BIOGEN INC. is 8.8x more valuable than Denali Therapeutics Inc. by market capitalization ($28.68 B vs $3.27 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DNLI | BIIB |
|---|---|---|
| Market cap | $3.27 B | $28.68 B |
| US-listed rank | #1734 | #476 |
| Revenue (latest FY) | $0.00 | $9.89B |
| Net income (latest FY) | -$512.54M | $1.29B |
| Net margin | - | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 763 | 2,690 |
BIOGEN INC. is 8.8x more valuable than Denali Therapeutics Inc. by market capitalization ($28.68 B vs $3.27 B).
In their latest fiscal years, Denali Therapeutics Inc. reported $0.00 in revenue while BIOGEN INC. reported $9.89B.
Full pages: Denali Therapeutics Inc. and BIOGEN INC., or browse the full rankings.